Who We Are
Inspiration is a unique company with a unique story. Since our inception, we have been focused solely on hemophilia – and on being an agent of change for the hemophilia community. Not satisfied with the status quo of treatment options for their sons and the hundreds of thousands of other people with hemophilia around the world, our founders set out to change the hemophilia treatment landscape.
Today, as we work to build a sustainable, fully integrated biopharmaceutical company focused solely on hemophilia, we have assembled a highly experienced team with strong expertise in developing, manufacturing and commercializing products for hemophilia and other rare diseases. Amidst this growth, our founders remain intimately involved with the company, leading our Board of Directors. Together, we share a passion to make a difference in the lives of people with hemophilia. We also share a belief that each person living with hemophilia has his or her own unique story, and deserves the chance to lead the healthiest, best possible life.
How We Will Make a Difference
We are currently investigating a new recombinant factor IX (rFIX), which if approved by regulatory authorities, would be the first recombinant factor IX (rFIX) in over 15 years for people with hemophilia B. In addition, we are currently investigating another product that, if approved by regulatory authorities, would be the first and only recombinant porcine factor VIII (rpVIII) therapy for people with acquired hemophilia and people with hemophilia A with inhibitors.
It is estimated that only about a quarter of the approximately 400,000 people with hemophilia globally receive the treatment they need.1 – a statistic we believe is simply unacceptable. We are committed to broadening treatment choices for people with hemophilia and improving access to hemophilia care and treatment in for all people with hemophilia throughout the world.